

AgomAb Announces Two Oral Presentations at the EASL Liver Congress 2021

Ghent, Belgium, June 18th, 2021 – [AgomAb Therapeutics NV](#) ('AgomAb'), a biotherapeutics company developing agonistic antibodies for the regeneration of damaged tissue, announced today that two abstracts have been selected for oral presentations at the upcoming International Liver Congress™ hosted by the European Association for the Study of the Liver (EASL), held from June 23-26, 2021.

“We look forward to showcasing the exciting pharmacology of our HGF/MET agonistic antibody at the EASL conference,” **stated Paolo Michieli, Chief Scientific Officer at AgomAb Therapeutics.** “Being selected for two oral presentations is a testament of our innovative approach of regenerating tissue and restoring organ function by targeting the HGF/MET pathway.”

Oral presentation details:

Abstract #1: A MET-agonistic antibody mimicking hepatocyte growth factor accelerates liver regeneration and improves survival in mice undergoing carbon tetrachloride exposure and partial hepatectomy

Presented by Prof Paolo Michieli, PhD on June 25, 2021, at 08.45 CET

Abstract no. OS-687, Abstract session: Liver development and regeneration.

Abstract #2: A fully agonistic anti-MET antibody protects hepatocytes against acute and chronic injury, promotes fibrosis regression and restores liver function in cirrhotic mice

Presented by Virginia Morello, PhD on June 25, 2021, at 15.15 CET

Abstract no. OS-874, Abstract session: Targeting liver inflammation and fibrosis.

About AgomAb

AgomAb is pioneering therapies that modulate regenerative pathways to achieve structural tissue repair and functional organ recovery. Our growing pipeline of highly specific monoclonal antibodies is designed to treat a range of acute and chronic conditions that involve inflammatory, metabolic and fibrotic processes. By combining new scientific insights with robust development expertise, we are building a company to lead to the emergence of truly regenerative medicines.

Contacts

For AgomAb Therapeutics

E-Mail: info@agomab.com

Media Requests for AgomAb

Dr. Stephanie May or Dr. Laura Mittmann

Trophic Communications

Phone: +49 171 185 56 82 or + 49 151 5798 4222

E-Mail: agomab@trophic.eu